Editorial
Pharmacogenomics as a Design Input in Early‐Phase Drug Development
Clinical Pharmacology in Drug Development · 2026-11 · 15 (11)
DOI: 10.1002/cpdd.70125 ↗Kurz gefasst
Editorial in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 05.11.2026. Verfasst von Amalia M Issa. Beteiligte Einrichtung: Editor-in-Chief, Clinical Pharmacology in Drug Development, McGill University, Canada. Die Arbeit nennt 6 Literaturangaben. Gefördert von: No funding was obtained for this work..
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Editor-in-Chief, Clinical Pharmacology in Drug Development, McGill University, Canada.
Förderung
- No funding was obtained for this work.
Zitieren
APA
Issa, A. M. (2026). Pharmacogenomics as a Design Input in Early‐Phase Drug Development. Clinical Pharmacology in Drug Development, 15(11). https://doi.org/10.1002/cpdd.70125
Vancouver
Issa AM. Pharmacogenomics as a Design Input in Early‐Phase Drug Development. Clinical Pharmacology in Drug Development. 2026;15(11). doi:10.1002/cpdd.70125
BibTeX
@article{Issa2026,
author = {Issa, Amalia M},
title = {Pharmacogenomics as a Design Input in Early‐Phase Drug Development},
journal = {Clinical Pharmacology in Drug Development},
year = {2026},
volume = {15},
number = {11},
doi = {10.1002/cpdd.70125}
}
EUVIMED